Advanced in Nasopharyngeal Carcinoma

Dr. Barbara J. Gitlitz

Oncology
1441 Eastlake Ave, Nor 8302e, 
Los Angeles, CA 
Clinical Trials:Currently Recruiting for 1 Trial
Advanced in Nasopharyngeal Carcinoma
1441 Eastlake Ave, Nor 8302e, 
Los Angeles, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Barbara Gitlitz is an Oncologist in Los Angeles, California. Dr. Gitlitz is rated as an Advanced provider by MediFind in the treatment of Nasopharyngeal Carcinoma. Her top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Small Cell Lung Cancer (SCLC), and Lung Adenocarcinoma.

Her clinical research consists of co-authoring 46 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 1 article in the study of Nasopharyngeal Carcinoma.

Specialties
Oncology
Licenses
Internal Medicine in CA
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Optima Health
  • HMO
  • POS

Locations

1441 Eastlake Ave, Nor 8302e, Los Angeles, CA 90089

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Enrollment Status: Recruiting
Publish Date: July 03, 2024
Intervention Type: Other, Drug
Study Drug: Crizotinib
Study Phase: Phase 3
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Enrollment Status: Active_not_recruiting
Publish Date: December 17, 2025
Intervention Type: Other, Procedure, Biological, Drug
Study Phase: Not Applicable
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Active_not_recruiting
Publish Date: December 04, 2025
Intervention Type: Other, Drug
Study Drug: Erlotinib Hydrochloride
Study Phase: Phase 3
An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
Enrollment Status: Active_not_recruiting
Publish Date: December 04, 2025
Intervention Type: Drug
Study Drug: Entrectinib
Study Phase: Phase 2
A Dose Finding Study Followed by Phase II Randomized, Placebo-Controlled Study of Veliparib (ABT-888) Added to Chemoradiotherapy With Carboplatin and Paclitaxel for Unresectable Stage III Non-small Cell Lung Cancer (NSCLC), (NCI Study Number 8811)
A Dose Finding Study Followed by Phase II Randomized, Placebo-Controlled Study of Veliparib (ABT-888) Added to Chemoradiotherapy With Carboplatin and Paclitaxel for Unresectable Stage III Non-small Cell Lung Cancer (NSCLC), (NCI Study Number 8811)
Enrollment Status: Active_not_recruiting
Publish Date: November 14, 2025
Intervention Type: Other, Drug, Radiation
Study Drugs: Carboplatin, Paclitaxel, Veliparib
Study Phase: Phase 1/Phase 2
A Phase II Study of Epigenetic Therapy With Azacitidine and Entinostat With Concurrent Nivolumab in Subjects With Metastatic Non-Small Cell Lung Cancer.
A Phase II Study of Epigenetic Therapy With Azacitidine and Entinostat With Concurrent Nivolumab in Subjects With Metastatic Non-Small Cell Lung Cancer.
Enrollment Status: Completed
Publish Date: May 03, 2024
Intervention Type: Drug
Study Drugs: Azacitidine, Entinostat, Nivolumab
Study Phase: Phase 2
Genomics of Young Lung Cancer Study
Genomics of Young Lung Cancer Study
Enrollment Status: Completed
Publish Date: November 18, 2021
Intervention Type: Other
Phase 1/2, First-in-Human, Dose-Escalation Study of X-396 (Ensartinib) in Patients With Advanced Solid Tumors and Expansion Phase in Patients With ALK-positive Non-Small Cell Lung Cancer
Phase 1/2, First-in-Human, Dose-Escalation Study of X-396 (Ensartinib) in Patients With Advanced Solid Tumors and Expansion Phase in Patients With ALK-positive Non-Small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: October 06, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase II, Multi-center, Open-label, Five-arm Study to Evaluate the Efficacy and Safety of Oral Ceritinib Treatment for Patients With ALK-positive Non-small Cell Lung Cancer (NSCLC) Metastatic to the Brain and/or to Leptomeninges
A Phase II, Multi-center, Open-label, Five-arm Study to Evaluate the Efficacy and Safety of Oral Ceritinib Treatment for Patients With ALK-positive Non-small Cell Lung Cancer (NSCLC) Metastatic to the Brain and/or to Leptomeninges
Enrollment Status: Completed
Publish Date: April 21, 2020
Intervention Type: Drug
Study Phase: Phase 2
Collaborative Advanced Stage Tissue Lung Cancer (CASTLE) Network
Collaborative Advanced Stage Tissue Lung Cancer (CASTLE) Network
Enrollment Status: Terminated
Publish Date: January 10, 2020
Intervention Type: Other
Pilot Study of the Identification of the Molecular Signatures of Relapse in Small Cell Lung Cancer
Pilot Study of the Identification of the Molecular Signatures of Relapse in Small Cell Lung Cancer
Enrollment Status: Withdrawn
Publish Date: May 25, 2018
Intervention Type: Other
View 10 Less Clinical Trials

46 Total Publications

Reply to: "Improving the Reporting of Long-Term Effects in the IMpower010 Trial" and "Adjuvant Atezolizumab in Early-Stage Non-Small Cell Lung Cancer: Signals, Silences, and the Need for Methodological Clarity".
Reply to: "Improving the Reporting of Long-Term Effects in the IMpower010 Trial" and "Adjuvant Atezolizumab in Early-Stage Non-Small Cell Lung Cancer: Signals, Silences, and the Need for Methodological Clarity".
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: December 10, 2025
Similar Doctors
Distinguished in Nasopharyngeal Carcinoma
Dr. Victoria M. Villaflor
Oncology | Hematology
Distinguished in Nasopharyngeal Carcinoma
Dr. Victoria M. Villaflor
Oncology | Hematology

Uc Regents

101 The City Dr S, 
Orange, CA 
 (26.1 miles away)
714-456-7004
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Victoria Villaflor is an Oncologist and a Hematologist in Orange, California. Dr. Villaflor is rated as a Distinguished provider by MediFind in the treatment of Nasopharyngeal Carcinoma. Her top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Salivary Gland Tumors, Gastrostomy, and Tissue Biopsy.

Advanced in Nasopharyngeal Carcinoma
Dr. Eddie H. Hu
Hematology | Oncology | Hematology Oncology
Advanced in Nasopharyngeal Carcinoma
Dr. Eddie H. Hu
Hematology | Oncology | Hematology Oncology

The Regents Of The University Of California

1411 S Garfield Ave, Suite 200, 
Alhambra, CA 
 (4.8 miles away)
626-588-2825
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Eddie Hu is a Hematologist and an Oncologist in Alhambra, California. Dr. Hu is rated as a Distinguished provider by MediFind in the treatment of Nasopharyngeal Carcinoma. His top areas of expertise are Breast Cancer, Colorectal Cancer, Familial Colorectal Cancer, Paget Disease of the Breast, and Bone Marrow Aspiration.

Advanced in Nasopharyngeal Carcinoma
Dr. Mark B. Agulnik
Oncology
Advanced in Nasopharyngeal Carcinoma
Dr. Mark B. Agulnik
Oncology

USC Care Medical Group Inc

1520 San Pablo St, 
Los Angeles, CA 
 (0.2 miles away)
800-872-2273
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Mark Agulnik is an Oncologist in Los Angeles, California. Dr. Agulnik is rated as an Elite provider by MediFind in the treatment of Nasopharyngeal Carcinoma. His top areas of expertise are Adult Soft Tissue Sarcoma, Synovial Sarcoma, Angiosarcoma, Osteotomy, and Colonoscopy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Gitlitz's expertise for a condition
ConditionClose
    View All 8 Advanced Conditions
    View All 19 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile